ICS/LABA Adherence and COPD Exacerbation

Completed

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adherent.

Key facts

Study ID

NCT02446041

Run by

AstraZeneca

People needed

10000

Starts

2015-05-01

Expected to finish

2015-10-01

Last updated by the study team

2016-10-11

Who can join

Age: 40 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• at least one prescription fill for ICS/LABA combination during identification period.
• COPD diagnosis
• 40 years or older at index date
• > or = 12 months of continuous health plan enrollment prior to and following index date
• 1 or more prescription for SABA, SAMA or SABA/SAMA during the pre-index period.

You may not qualify if…

• Patients with prescription claim for ICS/LABA combination therapy during the 12 month pre-index period
• Patients receiving oral corticosteroid medication for more than 180 days during the 12 month pre-index period
• Patients with cancer diagnosis in 12 month pre-index period

Where it is running

• Research Facility — Wilmington, Delaware, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.